uniQure
QURE | NASDAQ
$21.88
-$1.93 (-8.11%)
At close: Nov 16, 2026, 4:00 PM ET
$21.83
-$0.05 (-0.23%)
After-hours:
Nov 16, 2026, 7:54 PM ET
uniQure Company Profile
Company profile explainedCompany Profile
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Key Executives
| Name | Position |
|---|---|
| Matthew Craig Kapusta | Chief Executive Officer & Executive Director |
| Christian Klemt | Chief Financial Officer, Principal Financial Officer & GM of Amsterdam Site |
| Amin Abujoub | Chief Technical Operations Officer |
| Chiara Elizabeth Russo | Senior Director of Investor Relations |
| Erin Boyer | Chief People & Culture Officer |
| Hugo Katus | Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany |
| Jeannette Potts | Chief Legal & Compliance Officer and Corporate Secretary |
| Richard Porter | Chief Business & Scientific Officer |
| Tamara Tugal | Business Development Director |
| Walid Abi-Saab | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 16, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Sep 29, 2026 | 8-K | Current Report |
| Sep 02, 2026 | 8-K | Current Report |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Jul 29, 2026 | S-8 | Filing |
| Jul 29, 2026 | 10-Q | Quarterly Report |
| Jul 29, 2026 | 8-K | Current Report |
| Jul 20, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jul 16, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
uniQure
| Country | Netherlands |
| IPO Date | Feb 5, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 221 |
| CEO | Matthew C. Kapusta |
Contact Details
Paasheuvelweg 25 Amsterdam,
New Hampshire 1105 BP Netherlands
Stock Details
| Ticker Symbol | QURE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001590560 |
| CUSIP Number | n/a |
| ISIN Number | NL0010696654 |
| SIC Code | 2834 |
Recent News
- 3 days ago / seekingalpha.comuniQure: A Breakthrough In Huntington's, With A Market Too Large To Ignore
- 3 days ago / marketbeat.comuniQure CEO Defends Huntington's Therapy Data, Sees Opportunity Ahead of FDA Decision
- 3 days ago / zacks.comQURE Stock Rallies 17.5% in a Month: What Should Investors Do Now?
- 3 days ago / marketbeat.comuniQure Prepares for Potential FDA Panel on Huntington's Gene Therapy After Priority Review Nod
- 13 days ago / marketbeat.comuniQure Q3 Earnings Call Highlights
- 13 days ago / seekingalpha.comuniQure N.V. (QURE) Q3 2026 Earnings Call Transcript
- 13 days ago / zacks.comuniQure (QURE) Reports Q3 Loss, Misses Revenue Estimates
- 13 days ago / globenewswire.comuniQure Announces Third Quarter 2026 Financial Results and Provides Company Update
- 15 days ago / benzinga.comFDA Pushes uniQure Huntington Therapy Forward, Analyst Brushes Off Softening Signals
- 15 days ago / globenewswire.comuniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington's Disease
Add to Watchlist
Select watchlists to add or remove QURE